Pfizer has settled an ongoing battle with Teva Pharmaceuticals and several other parties to prevent the sale of Teva’s copycat version of the world’s best-selling drug, Lipitor (atorvastatin).

Under the terms of the agreement Teva, Phoenix Healthcare Distribution, Barclay Pharmaceuticals, AAH Pharmaceuticals, L Rowland & Co and Day Lewis will not the generic before May 2012, when the patent expires.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Pfizer commenced legal proceedings against Teva and three major wholesalers in July.

Upon the decision of a full trial, Pfizer said in a statement that Teva acknowledges that the Lipitor patent is valid and infringed by Teva’s product.

In November, Pfizer will launch a chewable low-dose version of Lipitor in the EU.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now